Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 4/30/15  and contains information from public web pages and contributions from the ZoomInfo community.

Ms. Klara A. Dickinson

Wrong Klara A. Dickinson?

Senior Vice President, Chief Regu...

Phone: (510) ***-****  HQ Phone
Email: k***@***.com
Anthera Pharmaceuticals , Inc.
25801 Industrial Boulevard Suite B
Hayward , California 94545
United States

Company Description: Anthera is a young and dynamic pharmaceutical company located in the Bay Area. Our mission is to develop and advance promising clinical products for the treatment...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • BS , biology
    College of Great Falls
  • B.S. , Biology
    College of Great Falls
28 Total References
Web References
Anthera Pharmaceuticals - Senior Management
www.anthera.com, 30 April 2015 [cached]
Klara A. Dickinson - Senior Vice President and Chief Regulatory Officer
Ms. Dickinson served as Senior Vice President of Regulatory Affairs and Compliance at Hyperion Therapeutics Inc. from October 2007 to July 2014. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for Hyperion Therapeutics' initial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid for use as a nitrogen-binding agent for chronic management of adult and pediatric patients =2 years of age with urea cycle disorders (UCDs). Prior to Hyperion Therapeutics, Ms. Dickinson spent three years at CoTherix, Inc and was most recently Vice President, Regulatory Affairs and Healthcare Compliance Officer from January 2004 to January 2007. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for CoTherix's initial product, Ventavis® (iloprost) Inhalation Solution. Prior to CoTherix, Inc., Ms. Dickinson held various positions at biopharmaceutical companies Scios, Inc. and DEY Laboratories, a subsidiary of Mylan, Inc. Ms. Dickinson holds a BS in Biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board.
Hyperion Therapeutics – Our Leadership Team
hyperiontx.com, 19 July 2013 [cached]
Klara A. Dickinson
Senior Vice President, Regulatory Affairs and Compliance
Klara A. Dickinson has served as our Senior VP, Regulatory Affairs and Compliance since October 2007. Ms. Dickinson previously spent 3 years with CoTherix, Inc. and most recently served as VP, Regulatory Affairs and Healthcare Compliance Officer for the company. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for the company's initial product, Ventavis® (iloprost) Inhalation Solution. Ms. Dickinson has also held various positions at Scios, Inc. and Dey Laboratories, a subsidiary of Mylan Inc.
Ms. Dickinson holds a BS in biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board.
Form 10-K
www.sec.gov, 14 Mar 2006 [cached]
Klara A. Dickinson
...
Klara A. Dickinson is Vice President, Regulatory Affairs of CoTherix.Ms. Dickinson joined CoTherix in January 2004 as Director, Regulatory Affairs and was promoted to Vice President in September 2004.Prior to CoTherix, Ms. Dickinson spent six years at Scios, Inc., a biopharmaceutical company, serving most recently as Associate Director of Regulatory Affairs.From 1993 to 1997, she held several positions in the Quality Control and Regulatory Affairs departments at DEY Laboratories, a biopharmaceutical company.Ms. Dickinson holds a B.S. in biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board.
Joining Co-Founder Chris Rivera ...
www.biospace.com, 4 Oct 2007 [cached]
Joining Co-Founder Chris Rivera (President and CEO) are Marvin Garovoy, M.D. (Senior Vice President (SVP), Clinical Development), Sharron Gargosky, PhD (Chief Scientific Officer and SVP of Corporate Development), Klara Dickinson (SVP, Regulatory Affairs and Compliance), Kevin Weber (SVP, Global Strategy and Operations), Wayne Davis, PhD (Vice President, Clinical Operations), Hoi Leung, PhD (Vice President, Biostatistics), George Jue (Vice President, Finance and Controller), and James Kaser (Vice President, Global Sales).
...
Klara A. Dickinson, Senior Vice President, Regulatory Affairs and Compliance, was previously Vice President of Regulatory Affairs and Healthcare Compliance Officer at CoTherix, Inc.In this role, Ms. Dickinson led the filing of the NDA and label negotiations for the company's initial product, Ventavis® (iloprost) Inhalation Solution, an orphan drug.Prior to CoTherix, Ms. Dickinson was at Scios, Inc. as Associate Director of Regulatory Affairs where she was instrumental in securing regulatory approval for Natrecor® (nesiritide).From 1993 to 1997, she held several positions in the Quality Control and Regulatory Affairs departments at DEY Laboratories.
Anthera Pharmaceuticals Announces ...
www.providenthp.com, 7 Jan 2015 [cached]
Anthera Pharmaceuticals Announces Appointment of Klara A. Dickinson as Senior Vice President, Chief Regulatory Officer Provident - Article
...
Anthera Pharmaceuticals Announces Appointment of Klara A. Dickinson as Senior Vice President, Chief Regulatory Officer
HAYWARD, Calif., Jan. 7, 2015 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced the appointment of Klara A. Dickinson as Senior Vice President, Chief Regulatory Officer.
"We're fortunate to have Klara join our team as we enter this phase of our product development efforts," said Paul F. Truex, Anthera's President and CEO.
...
"I'm excited to join Anthera during such important stages for both Sollpura and blisibimod," said Ms. Dickinson. "I look forward to sharing my regulatory expertise as we move forward with each of our development programs."
Ms. Dickinson served as Senior Vice President of Regulatory Affairs and Compliance at Hyperion Therapeutics Inc. from October 2007 to July 2014. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for Hyperion Therapeutics' initial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid for chronic management of adult and pediatric patients >2 years of age with urea cycle disorders (UCDs). Prior to Hyperion Therapeutics, Ms. Dickinson spent three years at CoTherix, Inc and was most recently Vice President, Regulatory Affairs and Healthcare Compliance Officer from January 2004 to January 2007. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for CoTherix's initial product, Ventavis ® (iloprost) Inhalation Solution. Prior to CoTherix, Inc., Ms. Dickinson held various positions at biopharmaceutical companies Scios, Inc. and DEY Laboratories, a subsidiary of Mylan, Inc. Ms. Dickinson holds a BS in Biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board.
Other People with the name "Dickinson":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.